BRTX — Biorestorative Therapies Cashflow Statement
0.000.00%
Last trade - 00:00
- $8.46m
- -$2.59m
- $0.15m
- 16
- 22
- 30
- 12
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -14.6 | -11.3 | -44.3 | -18.5 | -14.4 |
Depreciation | |||||
Non-Cash Items | 6.97 | 8.61 | 40.6 | 12.4 | 7.3 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.54 | 0.572 | 0.325 | 0.014 | 0.515 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -6.92 | -1.96 | -3.33 | -5.91 | -6.43 |
Capital Expenditures | -0.036 | — | -0.031 | -0.44 | -0.171 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | — | — | — | -13 | 3.42 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.036 | — | -0.031 | -13.4 | 3.25 |
Financing Cash Flow Items | 0 | -0.5 | 0 | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 6.84 | 5.03 | 21.3 | — | 2.35 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.116 | 3.06 | 18 | -19.3 | -0.827 |